These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 32179499)

  • 1. Drug resistance in liver flukes.
    Fairweather I; Brennan GP; Hanna REB; Robinson MW; Skuce PJ
    Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():39-59. PubMed ID: 32179499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy?
    Fairweather I
    Vet Parasitol; 2011 Aug; 180(1-2):133-43. PubMed ID: 21703766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Threat of Triclabendazole Resistance in Fasciola hepatica.
    Kelley JM; Elliott TP; Beddoe T; Anderson G; Skuce P; Spithill TW
    Trends Parasitol; 2016 Jun; 32(6):458-469. PubMed ID: 27049013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasciola hepatica: a comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology.
    Hanna RE; McMahon C; Ellison S; Edgar HW; Kajugu PE; Gordon A; Irwin D; Barley JP; Malone FE; Brennan GP; Fairweather I
    Vet Parasitol; 2015 Jan; 207(1-2):34-43. PubMed ID: 25529143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes after treatment in vivo with TCBZ and the related benzimidazole derivative, Compound Alpha.
    Hanna RE; Edgar HW; McConnell S; Toner E; McConville M; Brennan GP; Devine C; Flanagan A; Halferty L; Meaney M; Shaw L; Moffett D; McCoy M; Fairweather I
    Vet Parasitol; 2010 Mar; 168(3-4):240-54. PubMed ID: 20053501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding triclabendazole resistance.
    Brennan GP; Fairweather I; Trudgett A; Hoey E; McCoy ; McConville M; Meaney M; Robinson M; McFerran N; Ryan L; Lanusse C; Mottier L; Alvarez L; Solana H; Virkel G; Brophy PM
    Exp Mol Pathol; 2007 Apr; 82(2):104-9. PubMed ID: 17398281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal amplification of Fasciola hepatica in Galba truncatula: within and between isolate variation of triclabendazole-susceptible and -resistant clones.
    Hodgkinson JE; Cwiklinski K; Beesley N; Hartley C; Allen K; Williams DJL
    Parasit Vectors; 2018 Jun; 11(1):363. PubMed ID: 29941045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for high genetic diversity of NAD1 and COX1 mitochondrial haplotypes among triclabendazole resistant and susceptible populations and field isolates of Fasciola hepatica (liver fluke) in Australia.
    Elliott T; Muller A; Brockwell Y; Murphy N; Grillo V; Toet HM; Anderson G; Sangster N; Spithill TW
    Vet Parasitol; 2014 Feb; 200(1-2):90-6. PubMed ID: 24360656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
    Alvarez LI; Solana HD; Mottier ML; Virkel GL; Fairweather I; Lanusse CE
    Parasitology; 2005 Oct; 131(Pt 4):501-10. PubMed ID: 16174415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations.
    Elliott TP; Spithill TW
    Mol Biochem Parasitol; 2014 Nov; 198(1):45-7. PubMed ID: 25481750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of vitellogenesis and spermatogenesis by triclabendazole (TCBZ) in a TCBZ-resistant isolate of Fasciola hepatica following incubation in vitro with a P-glycoprotein inhibitor.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Parasitology; 2014 Jul; 141(8):1064-79. PubMed ID: 24889697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardisation of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica.
    Flanagan AM; Edgar HW; Forster F; Gordon A; Hanna RE; McCoy M; Brennan GP; Fairweather I
    Vet Parasitol; 2011 Feb; 176(1):34-42. PubMed ID: 21093156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.
    Ceballos L; Moreno L; Alvarez L; Shaw L; Fairweather I; Lanusse C
    BMC Vet Res; 2010 Feb; 6():8. PubMed ID: 20128898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2011 Oct; 109(4):981-95. PubMed ID: 21442257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasciola hepatica: histological demonstration of apoptosis in the reproductive organs of flukes of triclabendazole-sensitive and triclabendazole-resistant isolates, and in field-derived flukes from triclabendazole-treated hosts, using in situ hybridisation to visualise endonuclease-generated DNA strand breaks.
    Hanna RE; Forster FI; Brennan GP; Fairweather I
    Vet Parasitol; 2013 Jan; 191(3-4):240-51. PubMed ID: 23062689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The soluble glutathione transferase superfamily: role of Mu class in triclabendazole sulphoxide challenge in Fasciola hepatica.
    Stuart RB; Zwaanswijk S; MacKintosh ND; Witikornkul B; Brophy PM; Morphew RM
    Parasitol Res; 2021 Mar; 120(3):979-991. PubMed ID: 33501588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A major locus confers triclabendazole resistance in Fasciola hepatica and shows dominant inheritance.
    Beesley NJ; Cwiklinski K; Allen K; Hoyle RC; Spithill TW; La Course EJ; Williams DJL; Paterson S; Hodgkinson JE
    PLoS Pathog; 2023 Jan; 19(1):e1011081. PubMed ID: 36701396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia.
    Elliott TP; Kelley JM; Rawlin G; Spithill TW
    Vet Parasitol; 2015 Apr; 209(1-2):117-24. PubMed ID: 25771931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effects of triclabendazole (TCBZ) on the excretory-secretory products (ESP) of Fasciola spp parasites.
    Farahnak A; Golmohamdi T; Eshraghian M
    Acta Med Iran; 2012; 50(3):164-8. PubMed ID: 22418984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Vet Parasitol; 2012 Feb; 184(1):37-47. PubMed ID: 21872399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.